In a phase 1 study, 80 % (28 out of 35) patients
showed tumor shrinkage on scans.
Not exact matches
Trebananib does not increase the risks of hypertension (high blood pressure) and bowel perforation like bevaciuzmab, but still has a similar impact on
tumor shrinkage and delaying cancer progression, research
shows.
These findings provide further evidence of ONC201 as an inhibitor of cancer stem cells and support ongoing clinical trials in prostate cancer and glioblastoma that have
shown evidence of
tumor shrinkage.
Results
showed that antibodies were able to bind to the cancer cells and recruited specific immune cells called natural killer cells, resulting in
shrinkage of the
tumor, significantly improving survival.